NCT00951535 2026-04-17
A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17
Cancer Trials Ireland
Phase 2 Active not recruiting
Clinical Trials
92 trialsNCT02225704 2026-04-13
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
Phase 2 Completed
NCT03869762 2026-04-13
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04663997 2026-03-27
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04597359 2026-03-23
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT02905318 2026-03-09
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04322318 2026-02-24
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Children's Oncology Group
Phase 2 Recruiting
NCT06972615 2026-02-17
Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy
BLATAM
Phase 2 Not yet recruiting
NCT03768570 2026-02-02
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT05806515 2026-01-29
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
SWOG Cancer Research Network
Phase 2 Recruiting
NCT02972060 2025-09-19
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT03385655 2025-08-21
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT02788773 2025-05-15
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT01309672 2025-02-26
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
SWOG Cancer Research Network
Phase 2 Completed
NCT06783348 2025-01-23
RENALUT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Not yet recruiting
NCT04871529 2024-12-30
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
SWOG Cancer Research Network
Phase 2 Terminated
NCT06582628 2024-12-02
TEAM PC
Fundacion Oncosur
Phase 2 Recruiting
NCT00981656 2024-09-19
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02177695 2024-09-19
COXEN
SWOG Cancer Research Network
Phase 2 Completed
NCT06310369 2024-07-22
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Not yet recruiting
NCT05563558 2024-06-11
PEAPOD_FOS
Fundacion Oncosur
Phase 2 Recruiting
NCT06377722 2024-04-26
Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
Fundacion Oncosur
Phase 2 Terminated
NCT01331083 2023-08-22
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02033993 2023-08-22
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
Canadian Cancer Trials Group
Phase 2 Completed
NCT00075660 2023-08-04
3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00093457 2023-08-04
Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00258388 2023-08-04
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Canadian Cancer Trials Group
Phase 2 Completed
NCT01075308 2023-08-04
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT01619813 2023-08-04
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00068393 2023-07-07
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00002914 2023-06-22
Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003129 2023-06-22
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003308 2023-06-22
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003518 2023-06-22
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003871 2023-06-22
PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00005644 2023-06-22
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00005847 2023-06-22
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00039429 2023-06-22
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00053209 2023-06-22
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00004223 2023-06-18
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00077129 2023-06-18
Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003614 2023-06-15
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01164228 2023-06-15
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00771017 2023-05-25
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT00450411 2022-06-21
Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00777491 2022-06-15
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01434290 2022-06-09
Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02452554 2022-01-13
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Children's Oncology Group
Phase 2 Completed
NCT01566747 2021-12-23
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
Cancer Trials Ireland
Phase 2 Completed